New Delhi, March 5 -- Biocon Pharma, a subsidiary of the company, has obtained final approval from the US Food and Drug Administration (US FDA) for two of its Abbreviated New Drug Applications (ANDAs) - Lenalidomide capsules and Dasatinib tablets. Lenalidomide is prescribed for adults with multiple myeloma, mantle cell lymphoma, and anemia associated with myelodysplastic syndromes, while Dasatinib tablets are used to treat Philadelphia chromosome-positive chronic myeloid leukemia. Additionally, Biocon Pharma received tentative approval for its ANDA for Rivaroxaban tablets, which are indicated for the treatment of deep vein thrombosis and pulmonary embolism.

The provider of digital services and solutions company Coforge has entered into a...